Surgery in Non–Small-Cell Lung Cancer

Article

Surgical management of the patient with non–small-cell lung cancer (NSCLC) is complex. When should stereotactic body radiation therapy be used? What are the advantages of video-assisted thoracic surgery? Test your knowledge in our latest quiz.

Surgical management of the patient with non–small-cell lung cancer (NSCLC) is complex. When should stereotactic body radiation therapy be used? What are the advantages of video-assisted thoracic surgery? Test your knowledge in our latest quiz.

Question 1

Answer and Question 2 on Next Page »

Answer

B.

Surgery in patients with one N2 lymph node station involved by a lymph node smaller than 3 cm.

This practice pattern was selected by 90.5% of the member institutions, according to the NCCN. In addition, 80% said they would use endobronchial ultrasound with or without endoscopic ultrasound in initial evaluation of the mediastinum, and 40.5% noted they would use pathologic evaluation of the mediastinum, after neoadjuvant therapy, to make a final decision before surgery.

Question 2

Answer and Question 3 on Next Page »

Answer

C.

5 cm

The guidelines note that such patients should be counseled about the subsequent risk of locoregional and distant failure.

Question 3

Answer and Question 4 on Next Page »

Answer

C.

Race

The study found that half of patients alive at 5 years were alive at 10 years, with 10-year survival “associated with younger age, earlier stage, non-squamous histology, lobectomy, and fewer comorbidities, but not race.”

Question 4

Answer and Question 5 on Next Page »

Answer

B.

True

The study compared overall survival and lung cancer–specific survival among patients after lobectomy, segmentectomy, or wedge resection.

Question 5

Answer on Next Page »

Answer

D.

All of the above

VATS is also associated with a shorter length of hospitalization, minimal locoregional recurrence, and improved discharge independence in older and high-risk patients, according to the guidelines.

Recent Videos
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Related Content
© 2024 MJH Life Sciences

All rights reserved.